TuHURA Biosciences, Inc./NV (HURA): Nasdaq/NYSE listing notice — Kintara Therapeutics receives Nasdaq bid price noncompliance notice; also equity deficiency

TuHURA Biosciences, Inc./NV

Received Nasdaq notice on Dec 13, 2023 for failing to maintain $1.00 minimum bid price for 30 consecutive days.
Has 180 days (until June 10, 2024) to regain compliance by closing at $1.00+ for 10 consecutive days.
Also not compliant with Nasdaq's $2.5M minimum stockholders' equity requirement.
If compliance not regained, common stock may be delisted to OTC markets, reducing liquidity.
Considering options including a reverse stock split to cure bid price deficiency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 13, 2023, Kintara Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pri

View on SEC.gov

1 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-23-070743

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.